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Diclofenac (DCF), a widely prescribed non-steroidal anti-
inﬂammatory drug (NSAID), causes adverse effects in liver
and gastrointestinal tract. Although a great number of studies
were devoted to clarify the underlying mechanisms, they are
still not clear. In vitro experiments have shown that DCF
affected mitochondrial respiration, inhibited ATP synthesis,
and collapsed mitochondrial membrane potential (Petrescu
and Tarba 1997; Moreno-Sanchez et al. 1999). Further, it
was found that DCF causes apoptosis in hepatocytes, most
likely via an oxidative stress-induced opening of mitochon-
drial permeability transition pore (Gomez-Lechon et al.
2003), and according to Inoue et al. (2004) the molecular
mechanism of DCF-induced apoptosis involves as an initial
step the generation of reactive oxygen species (ROS).
Compromised ATP biosynthesis caused by DCF was also
observed in kidney mitochondria and rat thymocytes (Krause
et al. 2003; Ng et al. 2006). Although it is known that brain
cells are highly dependent on energy production, which may
be compromised by inhibition of mitochondrial oxidative
phosphorylation, so far a limited number of studies are
known concerning DCF effects in brain. Decreased dopa-
mine (DA) levels have been demonstrated in mice brain after
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Abstract
Diclofenac (DCF) is a widely used non-steroidal anti-inﬂam-
matory drug, which also act as a mitochondrial toxin. As it is
known that selective mitochondrial complex I inhibition com-
bined with mild oxidative stress causes striatal dopaminergic
dysfunction, we tested whether DCF also compromise dopa-
minergic function in the striatum. [
3H]Dopamine ([
3H]DA)
release was measured from rat striatal slices after in vitro (2 h,
10–25 lmol/L) or in vivo (3 mg/kg i.v. for 28 days) DCF
treatment. In vitro treatment signiﬁcantly decreased [
3H]DA
uptake and dopamine (DA) content of the slices. H2O2
(0.1 mmol/L)-evoked DA release was enhanced. Intracellular
reactive oxygen species production was not signiﬁcantly
changed in the presence of DCF. After in vivo DCF treatment
no apparent decrease in striatal DA content was observed and
the uptake of [
3H]DA into slices was increased. The intensity
of tyrosine hydroxylase immunoreactivity in the striatum was
highly variable, and both decrease and increase were
observed in individual rats. The H2O2-evoked [
3H]DA release
was signiﬁcantly decreased and the efﬂuent contained a sig-
niﬁcant amount of [
3H]octopamine, [
3H]tyramine, and [
3H]b-
phenylethylamine. The ATP content and adenylate energy
charge were decreased. In conclusion, whereas in vitro DCF
pre-treatment resembles the effect of the mitochondrial toxin
rotenone, in vivo it rather counteracts than aggravates dopa-
minergic dysfunction.
Keywords: diclofenac, dopamine release, H2O2, oxidative
stress, striatum.
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  2007 The Authorsin vivo DCF treatment (Hassanein et al. 2004). Recently, two
other NSAIDs, tolmetin and sulindac, were shown to reduce
signiﬁcantly DA levels in rat striatum (Dairam et al. 2006).
In our recent study, we showed that in vitro and in vivo
treatment with the mitochondrial complex I inhibitor rote-
none decreased DA levels in striatum, inhibited DA uptake,
and enhanced the sensitivity of striatal DA release to
oxidative stress induced by H2O2 (Milusheva et al. 2005),
thus reproducing the neurochemical features of Parkinson’s
disease. We also demonstrated that rotenone and H2O2 have a
supra-additive impact on the release of monoamine trans-
mitters and that even a minimal mitochondrial deﬁcit could
predispose neurons to the harmful effect of subsequent
oxidative stress (Milusheva et al. 2003).
As DCF was recognized as a mitochondrial inhibitor, too,
the question arises whether it may mimic the effects of
rotenone on striatal dopaminergic neurotransmission. There-
fore, we studied the effect of acute and chronic DCF
treatment on the release of DA from rat striatal slices under
conditions of mild oxidative challenge.
Materials and methods
Chronic diclofenac treatment: implantation of osmotic pumps and
animal care
All animal experiments were performed in accordance with the
National Institute of Health Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional Animal
Care and Use Committee of the Hungarian Academy of Sciences.
We used male Sprague–Dawley rats (280–320 g). Alzet osmotic
minipumps (Alzet Corporation, Palo Alto, CA, USA) were ﬁlled
with DCF dissolved in equal volumes of dimethylsulfoxide (DMSO)
and polyethylene glycol (PEG-300) or with the solvent alone.
Pumps were kept in sterile 0.9% saline at 37 C overnight before the
operation. Ketamine (75 mg/kg) and xylazine (10 mg/kg) were
injected intramuscularly as anesthetics. Pumps were implanted
under the skin on the back of each animal and were attached to the
right jugular vein by a catheter. Sham-operated control rats received
DMSO : PEG (1 : 1) only. The treated rats received 3 mg/kg/day
DCF (calculation based on body weight at the time of surgery) for
28 days. Our preliminary experiments showed that pre-treatment
with higher dose of DCF (5–6 mg/kg/day) elicited toxic effects,
with high mortality of the experimental animals. Following surgery,
rats were monitored for behavior, weight, and overall health.
[
3H]Dopamine release
Rats were decapitated after a short ether stress and the brain was
quickly removed. Then the striatum was dissected out and sliced into
400-lm thick sections with a McIlwain tissue chopper (Bachofer,
Reutlingen, Germany). In some experiments, a full cross-section of
the brain, including the striatum and cortex, was cut for immuno-
histochemistry. All manipulations were performed on ice.
Slices were incubated in 1 mL of Krebs solution containing
5 lCi [
3H]dopamine ([
3H]DA) for 45 min and were continuously
gassed with a mixture of 95% O2 and 5% CO2 at 37ºC. After
incubation the slices were rinsed and transferred to tissue chambers
and perfused continuously with modiﬁed Krebs solution at a rate of
0.5 mL/min. After a 60-min pre-perfusion 3-min samples were
collected and assayed for [
3H]DA. The samples for HPLC analysis
of [
3H] metabolites were acidiﬁed by 15 lL of 1.9 mol/L perchloric
acid during the collection.
Oxidative stress was mimicked by addition of H2O2 to the Krebs
solution starting at the ninth minute of collection. In a separate set of
experiments striatal slices from non-treated rats were kept for 2 h in
Krebs solution containing 10 or 25 lmol/L DCF, then rinsed with
normal Krebs solution and loaded with the isotope.
At the end of the experiment, slices were homogenized in 0.5 mL
of 10% trichloroacetic acid. A 0.5-mL aliquot of the superfusate
and 0.1 mL of the tissue supernatant were added to 2 mL of scintil-
lation cocktail (Ultima Gold; Packard, Canberra, Australia). Tritium
was measured with a Packard 1900 TR liquid scintillation counter
using an internal standard. The release of tritium was calculated in
Bq/g and expressed as the percentage of the amount of radioactivity
in the tissue at the sample collection time (fractional release, %). The
net release evoked by H2O2 was calculated by the area-under-the-
curve method, i.e. subtracting the resting release calculated from
the pre-stimulation period, from the release measured during H2O2.
The tissue tritium uptake was determined as the sum release + the
tissue content after the experiment and expressed in Bq/g, which ref-
lectsthecontentofradioactivityoftheslicesafterthe60 minwashout
period, i.e. the radioactivity that is speciﬁcally taken up by the tissue.
HPLC determination of dopamine content, [
3H] metabolites, and
adenine nucleotides
For the simultaneous measurement of biogenic amines and adenine
nucleotides a liquid–liquid two-dimensional reversed-phase and ion
pair reversed-phase chromatographic separation was developed
(Baranyi et al., 2006). Brieﬂy, a Gilson liquid chromatographic
System with 715-operation software (Gilson Medical Electronics
Inc., Middletown, WI, USA) was used. For the enrichment a ‘trap-
column’ [15–25 lm Nucleosil C-18 (20 · 4.0)] (Sigma, St. Louis,
MA, USA) was inserted into a loop position. The separation of
neurotransmitters was performed on a 3 lm Discovery C18 HS F5
(150 · 4.0 mm) (Sigma) analytical column. The analysis of adenine
nucleotides was carried out at the ﬁrst 10 min with reversed-phase
buffer. The ﬂow rate increased from 0.6 to 1.0 mL/min, linearly. The
separation of catecholamines was accomplished with ion pair
reversed-phase buffer at constant ﬂow rate 1.0 mL/min. The
efﬂuents were monitored by UV, electrochemical, and radiochemical
detector. They were connected in a cascade line. The identiﬁcation
of the tritium labeled compounds was based upon the known
retention times of unlabeled standards.
At the end of release experiments the tissue slices were immedia-
tely frozen in liquid nitrogen. The perfusion ﬂuid was centrifuged
at 300 g (4500 rpm) for 10 min at 0–4 C; the supernatant was
kept at )20 C until analysis. For the analysis, 545-lL sample
volumes were diluted with 5 lLo f1 0
)5 mol/L dihydroxybenzyl
amine as an internal standard and 500 lL were injected.
After the preparation of striatum of chronically treated rats the
native tissue was frozen by liquid nitrogen. In case of in vitro
experiments, the slices were frozen after DCF pre-treatment. The
control slices were kept in normal Krebs solution before freezing.
The weighed frozen tissue was homogenized in an appropriate
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theophylline (as an internal standard) at 10 nmol/mL concentration
and 0.5 mmol/L sodium metabisulﬁte (antioxidant for biogenic
amines). The suspension was centrifuged at 300 g (4500 rpm) for
10 min at 0–4 C. The perchloric anion was precipitated by addition
of 10 lL of 1 mol/L KOH to 190 lL of the supernatant. The
precipitate was then removed by centrifugation at 3509 g. The
supernatant was kept at )20 C until analysis. The pellet was saved
for protein measurement according to Lowry et al. (1951). Tissue
content of DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and
homovanilic acid (HVA) were expressed in pmol/mg protein.
Intracellular ROS measurement
After decapitation coronal sections (300 lm) of the striatum were
cut with a vibratome (Vibratome 1000; TPI, St. Louis, MO, USA),
and transferred into a mesh-bottom holding chamber containing
artiﬁcial CSF (in mmol/L: NaCl 126, KCl 2.5, NaHCO3 26, CaCl2
2, MgCl2 2, NaH2PO4 1.25, and glucose 10) bubbled with a mixture
of 95% O2 +5 %C O 2, leaving the ﬁnal pH at 7.4. After 25-min
incubation at 32.5 C, the slices were kept at 25 C until the onset
of the experiments. ROS production was monitored by using 5-
(and-6)-chloromethyl-2¢,7¢-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA) sensitive to peroxynitrite, hydrogen peroxide, and
hydroxyl radical. Slices were loaded with 45 lmol/L CM-
H2DCFDA for 45 min at 25 C (Fekete et al. 2007). Then they
were submerged and superfused (3.5 mL/min) in an experimental
chamber mounted on a Gibraltar BX1 platform (Burleigh, Fishers,
NY, USA) and viewed with a 10· water immersion objective
(Olympus, Hamburg, Germany) on an Olympus BX50WI upright
microscope. Slices were excited at 488 ± 5 nm with a T.I.L.L.
Polychrome II monochromator (Planegg, Germany). The emitted
light (535 ± 25 nm) was detected by a cooled CCD camera
(Photometrics Quantix, Photometrix, Tucson, AZ, USA) and the
system was controlled with the Axon Imaging Workbench 4.0
software (Axon Instruments, Molecular Devices, Union City, CA,
USA). Visualization was performed by differential interference
contrast imaging. Intensity changes were measured off-line. Fol-
lowing the subtraction of the autoﬂuorescence of an unloaded slice
the actual intensity values were normalized to an exponential curve
ﬁtted to the baseline. Experiments on loaded slices but without drug
treatment conﬁrmed the exponential nature of the baseline.
Level of intracellular superoxide was measured by the superox-
ide-selective dye hydroethidine (HEt). The slices were bulk loaded
with 60 lmol/L HEt for 25 min at 25 C. Loading solutions were
prepared freshly for each experiment. We excited HEt at
495 ± 5 nm and detected emitted light (605 ± 37.5 nm) by the
cooled CCD imaging system described above.
Immunohistochemistry
Non-treated rats, sham-operated controls, and DCF chronically
treated animals were decapitated after a short ether stress and the
brain was quickly removed. The upper part of the striatum with
adjacent cortex was immersed in 4% p-formaldehyde, 0.5%
glutaraldehyde, and 15% saturated picric acid in 0.1 mol/L
phosphate buffer, pH 7.4, for 6 h. The tyrosine hydroxylase (TH)-
staining was performed as described before (Milusheva et al. 2005).
Avidin biotinylated complex reaction and detection of antigen–
antibody complexes was performed according to the Vector
Laboratories (Burlingame, CA, USA) prescription. Stained sections
were washed in water, dehydrated in xylene, and mounted in Canada
balsam. Staining was investigated with an Olympus CH30 micro-
scope at 10–40 magniﬁcations. Pictures were taken by Olympus
digital camera.
Materials
The following materials were used: [
3H]DA (speciﬁc activity 39 Ci/
mmol) from Amersham (Little Chalfont, UK); H2O2 (Reanal,
Budapest, Hungary); DCF, rotenone, DMSO, and PEG-300 (Sigma,
St Louis, MO, USA); and CM-H2DCFDA (Molecular Probes,
Eugene, OR, USA).
The composition of the Krebs solution was the following: (in
mmol/L) NaCl 113, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2,
NaHCO3 25, Na2EDTA 0.03, ascorbic acid 0.3, and glucose 11.5.
All solutions were prepared on the day of use.
Data analysis
All data were expressed as means ± SEM of n observations. The
statistical analysis was made by ANOVA followed by the Bonferroni
test (multiple comparisons) or Student’s t-test (pair-wise compari-
sons). Values of p < 0.05 were considered statistically signiﬁcant.
Adenylate energy charge (EC), introduced by Atkinson (1968),
was calculated accordingly:
EC ¼ð ½ ATP þ0:5½ADP Þ=ð½ATP þ½ ADP þ½ AMP Þ
The energy charge (EC) value represents the energy resources of
a cell as a function of the concentration of nucleotides. A biological
system is fully charged when ATP dominates over other adenine
nucleotides and the corresponding EC is close to one.
Results
In vitro diclofenac treatment
In control experiments [
3H]DA release was measured under
basal conditions and in response to H2O2. After 60-min pre-
perfusion, the basal efﬂux measured in the ﬁrst 3-min sample
was 0.84 ± 0.046% (n = 11), which remained relatively
constant during the subsequent sample collection. H2O2
(0.1–0.25 mmol/L) itself elicited a dose-dependent elevation
of [
3H]DA release (Fig. 1a and b). This effect of oxidative
stresswassigniﬁcantlyenhancedinDCFpre-treatedslices,but
only at the lower concentration of H2O2 (0.1 mmol/L) applied
(Fig. 1a). It should be pointed out, however, that the amounts
ofradioactivityreleasedinresponseto0.1 mmol/LH2O2were
similar in slices pre-treated by 10 or 25 lmol/L DCF
(14.76 ± 1.65%, n = 3, vs. 14.86 ± 1.14, n =5 ;p > 0.05),
respectively. Most likely 10 lmol/L of DCF was already
enoughtocausemaximumsensibilityofstriatalslicestoamild
oxidativestimuli.Similarly,[
3H]DAuptakeandDAcontentof
pre-treated slices were decreased, independently of the con-
centration of DCF (Fig 2a and b). The content of DOPAC and
HVA was also lower in pre-treated slices, suggesting a
compromised synthesis and decreased turnover of DA.
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of ROS, we used the dye CM-H2DCFDA sensitive to H2O2
(Fekete et al. 2007). Perfusion of 0.25 mmol/L H2O2
elevated the level of ROS in striatal slices kept under similar
conditions than in release experiments. Pre-treatment of the
slices with 25 lmol/L DCF inﬂuenced neither the baseline
level of ROS (data not shown) nor the ﬂuorescence increase
evoked by the administration of H2O2 (Fig. 3a, upper trace).
Similarly, pre-treatment with the mitochondrial complex I
inhibitor rotenone (5 lmol/L) failed to affect both the
baseline (data not shown) and the 0.25 mmol/L H2O2-
evoked increase of ROS level when compared with slices
pre-treated only by DMSO (the solvent of rotenone) (Fig. 3a,
lower trace). As measured by the superoxide-selective dye
HEt, administration of 25 lmol/L DCF did not have any
effect on superoxide level unlike 5 lmol/L of rotenone,
which increased it (Fig 3b).
In vivo DCF i.v. application
In contrast to the previous set, the uptake of tritium was
enhanced in slices of chronically treated rats (Fig. 4a).
However, there was no difference between the endogenous
DA content of sham-operated controls and of chronically
treated rats. The amount of DOPAC, on the other hand, was
signiﬁcantly decreased, while HVA showed a tendency
toward increase (Fig. 4b). Nucleotides composition was
signiﬁcantly changed in the slices from chronically treated
rats (Fig. 5a). A decrease in ATP content, with a simulta-
neous increase in ADP content could be observed, resulting
in the reduction of EC when compared with the sham-
operated controls (Fig 5b).
In contrast to stimulation of H2O2-evoked [
3H]DA release
by acute DCF treatment, in the chronically DCF-treated
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Fig. 1 Acute DCF pre-treatment of striatal slices (2 h at 37 C, con-
tinuous oxygenation) before incubation with the isotope increases the
sensitivity of dopaminergic neurotransmission to oxidative stress.
H2O2 was added to the perfusion ﬂuid at the third fraction in (a)
0.1 mmol/L and (b) 0.25 mmol/L concentration. Control, ﬁlled circles;
DCF 10 lmol/L, ﬁlled triangles; DCF 25 lmol/L, open squares. [
3H]DA
release is expressed as fractional release (for calculation see Mate-
rials and methods), as a function of time. Means ± SE of n observa-
tions are presented. The number of experiments is indicated in the
legend. ***p < 0.001, signiﬁcance versus the control non-pre-treated
slice.
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take (a) and dopamine content (b). The concentration of DCF is indi-
cated at the bottom of respective columns. The results are expressed
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3H]DA uptake and pmol/mg protein (dopamine content),
respectively. Means ± SE of n observations are presented. The
number of experiments is indicated below the columns.*p < 0.05,
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Diclofenac and dopaminergic transmission | 363animals, we observed a decreased response to oxidative
stress (Fig. 6a). The increase of [
3H]DA outﬂow after the
onset of oxidative condition developed with some delay and
did not reach the level of sham-operated control at the higher
concentration of H2O2 applied (Fig. 6b).
HPLC analysis of the composition of tritium label in the
efﬂuent was performed in two fractions (indicated by black
downward triangles at Fig. 6a): under resting conditions and
in response to H2O2 application for 27 min (corresponding to
the maximum release). Under resting conditions the efﬂuent
contained tritiated DA, DOPAC, HVA, 3-methyl-4-hydroxy-
phenyl glycol, 3-methyltyramine, noradrenaline, octopamine
(OCT), and tyramine (TYR) (Fig. 7a). In the fraction
corresponding to the maximum effect of 0.1 mmol/L H2O2
treatment, the proportion of DAwas higher as a percentage of
the whole tritium label (62.69 ± 1.44%, n =3 ,p < 0.001 vs.
resting: 38.98 ± 1.78%, n = 8) (Fig. 7a and b). In DCF
treated rats (black bars) signiﬁcant changes in the compo-
sition of tritium label were observed in the presence of H2O2.
The proportion of DOPAC and DA decreased, whereas that
of OCT and TYR signiﬁcantly increased (Fig 7b). Decrease
in DA and increase in OCT was also observed in the sample
before H2O2 application i.e. under resting conditions
(Fig 7a). In addition, another trace amine (TA), b-phenyl-
ethylamine (PEA) also appeared in the efﬂuent both under
resting conditions and under the treatment of H2O2. Similar
changes were observed with the higher concentration of
H2O2 (0.25 mmol/L, data not shown). It should be noted that
we could not observe the appearance of DA quinone, the
toxic oxidative metabolite of DA, detected in our previous
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Fig. 4 [
3H]DA uptake (a) increased while dopamine content (b)
remained unchanged in striatal slices from rats that have been
chronically treated with DCF (3 mg/kg/day) for 28 days. Note that
DOPAC was decreased. Sham-operated control rats received
DMSO : PEG (1 : 1) only. Continuous infusion of the drug was
achieved by subcutaneous implanted Alzet mini-pump connected to
the right jugular vein via catheter. The results are expressed in Bq/g
[
3H]DA uptake and pmol/mg protein (dopamine content), respectively.
Means ± SE of n observations are presented. The number of experi-
ments is given in parentheses.*p < 0.05, signiﬁcance versus the
sham-operated control.
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Fig. 3 In vitro measurement of ROS and superoxide level on striatal
slices induced by DCF and rotenone. (a) DCF (25 lmol/L, black, upper
trace; n = 2) or rotenone (5 lmol/L, black, lower trace; n = 3) did not
potentiate intracellular ROS production evoked by H2O2 (0.25 mmol/L)
compared with vehicle treatment (water and DMSO, respectively; grey
traces; n = 3). Treatment by DCF or rotenone for 1 h preceded H2O2
application. ROS level was monitored by using CM-H2DCFDA. Nor-
malized ROS curves are presented for each treatment. (b) Rotenone
(5 lmol/L; black line; n = 3) induced an increase in superoxide level
while DCF (25 lmol/L; grey line; n = 3) did not as measured by HEt.
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exposed to H2O2 (Milusheva et al. 2005).
Whereas no difference was observed in TH-immunoreac-
tivity in the striatum between sham-operated and non-treated
rats (Fig. 8, upper trace), the staining intensity was very
variable in different rats undergoing chronic i.v. DCF (3 mg/
kg/day) infusion. Some of these rats showed intense TH-
immunoreactivity, while low TH-staining was found in about
28% of the chronically treated animals, indicating the loss of
DA-synthesizing capacity of dopaminergic nerve terminals
(Fig. 8, lower trace). These observations are consistent with
poor penetration of the blood–brain barrier by DCF, reported
by Dehouck et al. (1992), and reﬂect the individual varia-
tions among experimental animals.
Discussion
Our in vitro results showed a signiﬁcant decrease of both DA
content and [
3H]DA uptake and an enhancement of the
release of [
3H]DA induced by low H2O2 concentration
(0.1 mmol/L) in response to acute DCF treatment, similarly
to that observed in our previous study in slices, undergone
in vitro rotenone treatment (Milusheva et al. 2005).
When we measured the changes in ROS level under
conditions of superimposed H2O2 stimulation, DCF failed to
enhance the effect of 0.25 mmol/L H2O2 both in the ROS-
related ﬂuorescence assay and in the release experiments.
Similarly, 25 lmol/L DCF did not inﬂuence superoxide level
contrary to rotenone, which induced an immediate superox-
ide production after its administration. This is most likely
because of the double face action of DCF on free radical
production, i.e. it could also act as a free radical scavenging
antioxidant (Sairam et al. 2003; Tang and Liu 2006). The
capability of DCF to induce mitochondrial dysfunction, e.g.
impaired ATP synthesis (Bort et al. 1998) does not neces-
sarily results in the increase of superoxide or other ROS
levels. Although Gomez-Lechon et al. (2003) showed a
signiﬁcant increase of intracellular ROS by in vitro DCF
treatment of hepatocytes, they observed such an effect at high
concentrations of the drug (350 and 450 lmol/L) and the
maximum effect was seen only after 5 h incubation. We
measured the effect of DCF on ROS production at a lower
and pharmacologically more relevant concentration. The
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production may also underlie the differences that they exert
on DA release.
Thus, while in vitro DCF mimics the effect of rotenone on
striatal DA release (Milusheva et al. 2005), in vivo it acts
substantially different. The ATP level was dramatically
decreased in slices from chronically DCF i.v. treated animals
compared with the sham-operated ones and the EC was
lowered. Our data are in accordance with the ﬁnding of Bort
et al. (1998) that DCF caused a fast depletion of ATP in
hepatocytes. Krause et al. (2003) have also demonstrated
uncoupling effect on mitochondrial respiration and inhibition
of ATP turnover by DCF in intact cells. Similarly, inhibition
of ATP biosynthesis by DCF was found in kidney mito-
chondria and cells (Ng et al. 2006).
However, despite the substantial energy depletion, the DA
content was not signiﬁcantly changed in in vivo DCF treated
rats. The TH immunoreactivity showed high variance among
individual rats, and a decrease was observed only in one third
of the animals, whereas in others no change or increase was
observed. The uptake of [
3H]DA was enhanced, and DA
release in response to H2O2 was diminished. HPLC analysis
of release samples revealed signiﬁcant changes in the efﬂuent
derived from the striata of DCF treated rats. However, these
changes were different from those observed in our previous
study using an identical protocol of in vivo rotenone
treatment. In response to DCF treatment the proportion of
DOPAC and DA decreased, whereas the proportion of TAs
(OCT, TYR, and PEA) increased. TAs, are formed from L-
phenylalanine and L-tyrosine by the aromatic amino acid
decarboxylase and normally contribute to a minority of
extracellular monoamine levels or remain undetectable
(Branchek and Blackburn 2003; Lindemann and Hoener
2005). Therefore, increased formation of TAs together with
5 mm
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Fig. 8 Immunostaining for TH in the striatal brain sections of Spra-
gue–Dawley rats. Staining was performed on 40-lm Vibratome sec-
tions of the brain tissue blocks containing the upper part of the striatum
with adjacent cortex. Fixation was performed by 4% p-formaldehyde,
0.5% glutaraldehyde, and 15% saturated picric acid in 0.1 mol/L
phosphate buffer, pH 7.4. Dilution of applied TH antibody (Sigma) was
1 : 1000. Detection of antigen–antibody complexes was performed by
DAB as chromogen. Original magniﬁcation: 10· S, striatum; C, cortex.
(a) Control staining. TH-antibody was omitted from the incubation
medium. Brain section from untreated animal. (b) Immunostaining for
TH in the brain section of untreated animal. Strong immunoreactivity in
the striatum. (c) Striatal brain section of a sham-operated Sprague–
Dawley rat. Intensity of immunostaining for TH antibody is comparable
with the control staining. (d, e, and f) Different intensity of the TH-
staining in the striatal sections after long-term (4 weeks) of DCF
treatment (selected samples from the results of TH-immunostaining of
eight treated animals). (d) Signiﬁcantly weaker immunoreactivity in the
striatum (two cases). (e) Intensity of the TH-staining is comparable
with the staining found in the striatal sections of sham-operated or
control animals (two cases). (f) TH-immunoreactivity is stronger after
DCF treatment than control (four cases).
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Fig. 7 Chronic i.v. DCF treatment decreases the proportion of tritiated
DA and 3,4-dihydroxyphenylacetic acid (DOPAC) in the efﬂuent,
however it increases the proportion of trace amines: octopamine
(OCT), tyramine (TYR), and b-phenylethylamine (PEA). Tritium con-
tent of the samples indicated by arrows on Fig 6a was analyzed by
HPLC. The samples contained tritiated DA, DOPAC, homovanilic acid
(HVA), 3-methyl-4-hydroxyphenyl glycol (MHPG), 3-methyltyramine
(3-MT), noradrenaline (NA), OCT, TYR, and PEA. (a) Resting efﬂuent,
collected 6 min after the start of collection period. (b) Efﬂuent
collected during the peak of the effect of 0.1 mmol/L H2O2 at 36 min.
Means ± SE of n observations are presented. The numbers of
experiments are given in the parentheses. *p < 0.05, **p < 0.01,
***p < 0.001, signiﬁcance versus the sham-operated controls.
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compromised synthesis of DA by the TH enzyme following
chronic DCF treatment, which is accompanied by a shift of
enzymatic activities to TA pathways. Although TAs also used
to increase if their metabolism by monoamine oxidase
enzyme were impeded, simultaneous DA accumulation in the
efﬂuent was not detected. It is also noteworthy that in
response to DCF treatment we could not observe the
appearance of DA quinone, the toxic oxidative metabolite
of DA formed in the presence of H2O2 after in vivo rotenone
treatment (Milusheva et al. 2005), and proposed to be a
potential source of free radical-induced damage of dopami-
nergic terminals. However, our data raised the question
whether the enhanced extracellular concentrations of TAs
following chronic DCF treatment might be associated with a
risk of neurological disorders for patients taking DCF over a
prolonged period, as TAs dysregulation has been linked to
various psychiatric diseases (Lindemann and Hoener 2005).
Taken together our in vivo data showed that chronic DCF
treatment does not aggravate the effect of oxidative stress on
dopaminergic transmission. It even decreased the suscepti-
bility of striatal dopaminergic terminals to mild oxidative
burden. In line with our in vivo data, we found marked
difference in the intracellular superoxide generating ability of
rotenone and DCF (see Fig 3b) and Sairam et al. (2003) have
found reduction of hydroxyl radical generation by DCF.
Recently, Dairam et al. (2006) have demonstrated the
antioxidant and free radical scavenging properties of two
other NSAIDs, tolmetin and sulindac, in hippocampal
neurones. The authors have suggested that NSAIDs, by
inhibiting cyclooxygenase activity, may act as indirect
antioxidants, because cyclooxygenase activity itself produces
ROS (Nikolic and Van Breemen 2001). This might be the
case with our in vivo experiments. DCF was also shown to
lower lipid peroxidation induced by Fe
2+/ascorbate system
and to accelerate decomposition of peroxynitrite (Mouithys-
Mickalad et al. 2000).
A further possible explanation of the opposite in vivo and
in vitro effects of DCF might be the actual concentration of
the drug at the target site. As a low penetration through the
blood–brain barrier was estimated for DCF (Dehouck et al.,
1992) it seems that in vivo DCF concentration in the striatum
was much lower than the concentration we used in vitro. The
variance in the intensity TH immunostaining might also
reﬂect individual levels of metabolic activity resulting in a
different rate of DCF decomposition in vivo. It was recently
shown that brain penetration of NSAIDs, including DCF,
might be modulated by cytokines (Fukuda et al. 2005) and
therefore it may vary between individuals.
In conclusion, while in vitro DCF treatment mimics the
effect of rotenone on striatal dopaminergic transmission,
in vivo it rather counteracts than aggravates dopaminergic
neurodegeneration. However, it should be kept in mind that it
might be potentially toxic to individuals with altered integrity
of blood–brain barrier which increases the risk of side-effects
in the CNS.
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